RELENZA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Relenza, and when can generic versions of Relenza launch?
Relenza is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in RELENZA is zanamivir. One supplier is listed for this compound. Additional details are available on the zanamivir profile page.
Summary for RELENZA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 84 |
Clinical Trials: | 9 |
Patent Applications: | 5,305 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for RELENZA |
What excipients (inactive ingredients) are in RELENZA? | RELENZA excipients list |
DailyMed Link: | RELENZA at DailyMed |
Recent Clinical Trials for RELENZA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Oxford | Phase 2 |
Hospital Authority | Phase 3 |
Food and Health Bureau, Hong Kong | Phase 3 |
Pharmacology for RELENZA
Drug Class | Neuraminidase Inhibitor |
Mechanism of Action | Neuraminidase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for RELENZA
US Patents and Regulatory Information for RELENZA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RELENZA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | RELENZA | zanamivir | POWDER;INHALATION | 021036-001 | Jul 26, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for RELENZA
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
GlaxoSmithKline Trading Services Limited | Dectova | Zanamivir | EMEA/H/C/004102 Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when:The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orOther anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.Dectova should be used in accordance with official guidance. |
Authorised | no | no | no | 2019-04-26 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for RELENZA
See the table below for patents covering RELENZA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Poland | 149733 | ⤷ Try a Trial | |
China | 1502621 | ⤷ Try a Trial | |
China | 1143853 | ⤷ Try a Trial | |
Singapore | 6889 | ⤷ Try a Trial | |
Croatia | P930455 | ANTIVIRAL COMPOUNDS | ⤷ Try a Trial |
Finland | 105478 | ⤷ Try a Trial | |
Greece | 3026225 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RELENZA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0526543 | SPC/GB99/030 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ZANAMIVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR DERIVATIVE; REGISTERED: SE 14997 19990209; UK PL10949/0327 19990625 |
0526543 | 99C0042 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ZANAMIVIR; NAT. REGISTRATION NO/DATE: 725 IS 380 F 11 19990906; FIRST REGISTRATION: SE 14997 19990209 |
0526543 | C990030 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ZANAMIVIRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBARE ESTER; NAT. REGISTRATION NO/DATE: RVG 24094 19990707; FIRST REGISTRATION: 14997 19990209 |
0526543 | 34/1999 | Austria | ⤷ Try a Trial | PRODUCT NAME: ''ZANAMIVIR'' GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER DERIVATS; NAT. REGISTRATION NO/DATE: 1-23120 19990702; FIRST REGISTRATION: SE 14997 19990209 |
0208846 | 99C0032 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ZANAMIVIR; NAT. REGISTRATION NO/DATE: NL 24 551 19990726; FIRST REGISTRATION: SE - 14 997 19990209 |
0526543 | 990030 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ZANAMIVIRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT EN/OF VAN EEN FARMACEUTISCH AANVAARDBARE ESTER; NATL. REGISTRATION NO/DATE: RVG 24094 19990707; FIRST REGISTRATION: SE 14997 19990209 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |